115 related articles for article (PubMed ID: 33523652)
1.
Vantourout JC; Mason AM; Yuen J; Simpson GL; Evindar G; Kuai L; Hobbs M; Edgar E; Needle S; Bai X; Wilson S; Scott-Stevens P; Traylen W; Lambert K; Young N; Bunally S; Summerfield SG; Snell R; Lad R; Shi E; Skinner S; Shewchuk L; Watson AJB; Chung CW; Pal S; Holt DA; Kallander LS; Prendergast J; Rivera K; Washburn DG; Harpel MR; Arico-Muendel C; Isidro-Llobet A
Bioconjug Chem; 2021 Feb; 32(2):279-289. PubMed ID: 33523652
[TBL] [Abstract][Full Text] [Related]
2. Multivalent Albumin-Neonatal Fc Receptor Interactions Mediate a Prominent Extension of the Serum Half-Life of a Therapeutic Protein.
Yang B; Kwon I
Mol Pharm; 2021 Jun; 18(6):2397-2405. PubMed ID: 33983743
[TBL] [Abstract][Full Text] [Related]
3. Prolonged half-life of small-sized therapeutic protein using serum albumin-specific protein binder.
Kim TY; Park JH; Shim HE; Choi DS; Lee DE; Song JJ; Kim HS
J Control Release; 2019 Dec; 315():31-39. PubMed ID: 31654685
[TBL] [Abstract][Full Text] [Related]
4. Serum albumin-binding V
van Faassen H; Ryan S; Henry KA; Raphael S; Yang Q; Rossotti MA; Brunette E; Jiang S; Haqqani AS; Sulea T; MacKenzie CR; Tanha J; Hussack G
FASEB J; 2020 Jun; 34(6):8155-8171. PubMed ID: 32342547
[TBL] [Abstract][Full Text] [Related]
5. Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement.
Larsen MT; Rawsthorne H; Schelde KK; Dagnæs-Hansen F; Cameron J; Howard KA
J Control Release; 2018 Oct; 287():132-141. PubMed ID: 30016735
[TBL] [Abstract][Full Text] [Related]
6. Extracellular BMP1 is the major proteinase for COOH-terminal proteolysis of type I procollagen in lung fibroblasts.
N'Diaye EN; Cook R; Wang H; Wu P; LaCanna R; Wu C; Ye Z; Seshasayee D; Hazen M; Lin W; Tyagi T; Hotzel I; Tam L; Newman R; Roose-Girma M; Wolters PJ; Ding N
Am J Physiol Cell Physiol; 2021 Feb; 320(2):C162-C174. PubMed ID: 33206546
[TBL] [Abstract][Full Text] [Related]
7. Lysine reactivity profiling reveals molecular insights into human serum albumin-small-molecule drug interactions.
Yang S; Zhang W; Liu Z; Zhai Z; Hou X; Wang P; Ge G; Wang F
Anal Bioanal Chem; 2021 Dec; 413(30):7431-7440. PubMed ID: 34676431
[TBL] [Abstract][Full Text] [Related]
8. Extending the half-life of a fab fragment through generation of a humanized anti-human serum albumin Fv domain: An investigation into the correlation between affinity and serum half-life.
Adams R; Griffin L; Compson JE; Jairaj M; Baker T; Ceska T; West S; Zaccheo O; Davé E; Lawson AD; Humphreys DP; Heywood S
MAbs; 2016 Oct; 8(7):1336-1346. PubMed ID: 27315033
[TBL] [Abstract][Full Text] [Related]
9. Site-selective labeling of a lysine residue in human serum albumin.
Asano S; Patterson JT; Gaj T; Barbas CF
Angew Chem Int Ed Engl; 2014 Oct; 53(44):11783-6. PubMed ID: 25196737
[TBL] [Abstract][Full Text] [Related]
10. Comparative studies of the serum half-life extension of a protein via site-specific conjugation to a species-matched or -mismatched albumin.
Yang B; Kim JC; Seong J; Tae G; Kwon I
Biomater Sci; 2018 Jul; 6(8):2092-2100. PubMed ID: 29881837
[TBL] [Abstract][Full Text] [Related]
11. Enhanced therapeutic potential of antibody fragment via IEDDA-mediated site-specific albumin conjugation.
Go EB; Lee JH; Cho JH; Kwon NH; Choi JI; Kwon I
J Biol Eng; 2024 Apr; 18(1):23. PubMed ID: 38576037
[TBL] [Abstract][Full Text] [Related]
12. "Human and Mouse Cross-Reactive" Albumin-Binding Helix-Loop-Helix Peptide Tag for Prolonged Bioactivity of Therapeutic Proteins.
Nakatani Y; Ye Z; Ishizue Y; Higashi T; Imai T; Fujii I; Michigami M
Mol Pharm; 2022 Jul; 19(7):2279-2286. PubMed ID: 35635006
[TBL] [Abstract][Full Text] [Related]
13. Site-Specific Albumination as an Alternative to PEGylation for the Enhanced Serum Half-Life in Vivo.
Yang B; Lim SI; Kim JC; Tae G; Kwon I
Biomacromolecules; 2016 May; 17(5):1811-7. PubMed ID: 27050863
[TBL] [Abstract][Full Text] [Related]
14. Effect of C-terminus Conjugation via Different Conjugation Chemistries on In Vivo Activity of Albumin-Conjugated Recombinant GLP-1.
Park J; Bak M; Min K; Kim HW; Cho JH; Tae G; Kwon I
Pharmaceutics; 2021 Feb; 13(2):. PubMed ID: 33672039
[TBL] [Abstract][Full Text] [Related]
15. Structural basis of serum albumin recognition by SL335, an antibody Fab extending the serum half-life of protein therapeutics.
Cho SY; Han J; Cha SH; Yoon SI
Biochem Biophys Res Commun; 2020 Jun; 526(4):941-946. PubMed ID: 32284170
[TBL] [Abstract][Full Text] [Related]
16. Binding to Ocular Albumin as a Half-Life Extension Principle for Intravitreally Injected Drugs: Evidence from Mechanistic Rat and Rabbit Studies.
Fuchs H; Igney F
J Ocul Pharmacol Ther; 2017 Mar; 33(2):115-122. PubMed ID: 28055308
[TBL] [Abstract][Full Text] [Related]
17. Developmental roles of the BMP1/TLD metalloproteinases.
Ge G; Greenspan DS
Birth Defects Res C Embryo Today; 2006 Mar; 78(1):47-68. PubMed ID: 16622848
[TBL] [Abstract][Full Text] [Related]
18. Generation of therapeutic protein variants with the human serum albumin binding capacity via site-specific fatty acid conjugation.
Cho J; Lim SI; Yang BS; Hahn YS; Kwon I
Sci Rep; 2017 Dec; 7(1):18041. PubMed ID: 29269881
[TBL] [Abstract][Full Text] [Related]
19. A Dual Alkylated Peptide-ligand Enhances Affinity to Human Serum Albumin.
Nakhaei E; Takehara K; Sato H; Zai K; Kishimura A; Mori T; Katayama Y
Anal Sci; 2018; 34(4):501-504. PubMed ID: 29643315
[TBL] [Abstract][Full Text] [Related]
20. Structure, enzymatic activities, glycation and therapeutic potential of human serum albumin: A natural cargo.
Rabbani G; Ahn SN
Int J Biol Macromol; 2019 Feb; 123():979-990. PubMed ID: 30439428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
